

ASX ANNOUNCEMENT
Lifespote Health Ltd

16 January 2017

**Lifespote Health Ltd raises \$8.0M and aims to become a top player
in the global digital health industry**

- Lifespote Health Ltd successfully commenced trading on the ASX, backed by Top-Tier institutions, Global funds and Family offices
- A record month for BodyTel in December 2016, with month-on-month revenue growth of over 20%, well above budgeted forecasts. The strong underlying growth is expected to increase in 1Q17, further cementing the company's position in the global market for the management & monitoring of chronic diseases
- Discussions with new Global multinational companies relating to the roll-out of BodyTel's SaaS software progressing extremely well, with new contracts expected to be announced by the end of June quarter
- TGA approval process is underway with aim to be granted relevant approvals during Q1/Q2 2017
- Roll-out of BodyTel in the Australian market going well with key hires already in place

Successful Completion of A\$8.0 Million Capital Raising

Lifespote Health Ltd (ASX: LSH) ("Lifespote Health" or "Company"), an international digital health company focused on the management and monitoring of chronic diseases, has successfully completed its initial public offering to list on the ASX and its' Prospectus capital raising which was targeted at \$5m to 8m. The capital raise received strong support and was oversubscribed with the maximum amount of \$8m being raised. Lifespote Health was pleased to attract investment in the capital raising from top-tier global institutions and small cap funds, which invest strategically into Healthcare IT.

The successful capital raising will enable Lifespote Health to roll-out the already commercialized BodyTel System into new global markets (principally the European & Australian markets), with a strong focus on the development and commercialization of medical diagnostic and telemonitoring technologies in hospitals, clinics and multinational hardware companies.

For personal use only

The BodyTel System is a software system that facilitates the management of chronic diseases and assists with the measurement of key vital functions and indicators of these diseases (including, but not limited to blood glucose, blood pressure and weight levels), as well as assisting with the monitoring of prescribed therapies for chronic diseases (including medication dosages, diets and levels of physical activity), which globally is a \$34 billion addressable market.

BodyTel's technology is already operational in Europe, with existing paying customers including B.Braun, Anycare and TK Pharma.

Mark Talbot, non-executive Board member remarked: "I am extremely excited and overwhelmed by the interest and support we received from both retail and institutional clients, globally. This is just the start of an exciting journey and we look forward to delivering excellent returns to our shareholders."

Strong growth in second half of 2016 calendar year

The Company's 100% owned German subsidiary company, BodyTel GmbH, has finished the calendar year 2016 with strong operational growth, with second half revenues well-above budgeted numbers.

Having expanded the business with existing B2B partners such as B.Braun, BodyTel GmbH was able to close the month of December 2016 with a month-on-month growth of over 20%, which is expected to increase in 2017.

The Company is also in promising discussions with other global multinational companies to work together and integrate the Company's Software-as-a-Service (SaaS) model for the telemedical monitoring and management platform to collect patient data and connect them to dedicated caregivers such as doctors, hospitals, nurses or family members.

TGA approval expected Q1/Q2/2017

Lifspot Health has commenced processes with the Therapeutic Goods Administration (TGA) to allow for sale of the BodyTel System in Australia. The approval is targeted for completion in Q1/Q2 2017.

In addition to undertaking the TGA approval process, the Company is also commencing the establishment of the commercial operations in Australia which will include the addition of Australian – based employees who will be responsible to duplicate the European sales approach to Australia (Business Development, Admin, 2nd level Support, QA/RA, Key Accounting).

"Collecting data at the patient's home is just a necessary step." says Stefan Schraps, Managing Director of BodyTel. "What happens then is the key. How data is transferred to a secure and powerful system that combines everything it 'knows' about the patient, draws conclusions in real-time and feeds them back to the patient or authorized caregivers or loved ones. The advantage of the BodyTel System is that offers these digital monitoring and diagnostic functions to its users."

The Company is pleased to provide this update and will continue to provide updates as appropriate.

For personal use only

For further information on the Company's portfolio of projects please refer to the website at:
www.lifespot-health.com

ENDS

For further information:

Mr Niv Dagan
Corporate Advisor
Peak Asset Management

Mr Justyn Stedwell
Company Secretary
Lifespot Health Ltd

Phone: 1300 304 460
Mobile: 0402 912 198

Phone: 03 9041 6663

About Lifespot Health Ltd.

Lifespot Health operates within the digital health sector and is focused on developing and commercializing medical diagnostic and monitoring technology. Our systems and applications aim to bring efficiencies in the medical system to clients and end users, saving time and money.

Lifespot Health integrates software to combine enhanced sensor technology with self-learning algorithms, allowing patients to monitor chronic diseases and critical conditions with their smartphones.

Lifespot Health aims to become a global player in the management and monitoring of chronic diseases.

For personal use only